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Background: In sickle cell disease (SCD), the mitogen-activated protein kinase (MAPK) ERK1/2 is constitutively active
and can be inducible by agonist-stimulation only in sickle but not in normal human red blood cells (RBCs). ERK1/2
is involved in activation of ICAM-4-mediated sickle RBC adhesion to the endothelium. However, other effects of the
ERK1/2 activation in sickle RBCs leading to the complex SCD pathophysiology, such as alteration of RBC
hemorheology are unknown.
Results: To further characterize global ERK1/2-induced changes in membrane protein phosphorylation within
human RBCs, a label-free quantitative phosphoproteomic analysis was applied to sickle and normal RBC membrane
ghosts pre-treated with U0126, a specific inhibitor of MEK1/2, the upstream kinase of ERK1/2, in the presence or
absence of recombinant active ERK2. Across eight unique treatment groups, 375 phosphopeptides from 155
phosphoproteins were quantified with an average technical coefficient of variation in peak intensity of 19.8%. Sickle
RBC treatment with U0126 decreased thirty-six phosphopeptides from twenty-one phosphoproteins involved in
regulation of not only RBC shape, flexibility, cell morphology maintenance and adhesion, but also glucose and
glutamate transport, cAMP production, degradation of misfolded proteins and receptor ubiquitination. Glycophorin
A was the most affected protein in sickle RBCs by this ERK1/2 pathway, which contained 12 unique phosphorylated
peptides, suggesting that in addition to its effect on sickle RBC adhesion, increased glycophorin A phosphorylation
via the ERK1/2 pathway may also affect glycophorin A interactions with band 3, which could result in decreases in
both anion transport by band 3 and band 3 trafficking. The abundance of twelve of the thirty-six phosphopeptides
were subsequently increased in normal RBCs co-incubated with recombinant ERK2 and therefore represent specific
MEK1/2 phospho-inhibitory targets mediated via ERK2.
Conclusions: These findings expand upon the current model for the involvement of ERK1/2 signaling in RBCs.
These findings also identify additional protein targets of this pathway other than the RBC adhesion molecule
ICAM-4 and enhance the understanding of the mechanism of small molecule inhibitors of MEK/1/2/ERK1/2, which
could be effective in ameliorating RBC hemorheology and adhesion, the hallmarks of SCD.
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Sickle cell disease (SCD) is a hereditary blood disorder,
which comprises a class of hemoglobinopathies in which
a sickling variant of the β chain of hemoglobin (HbS,
containing Hbβ glu6→ val) is expressed. Sickle red blood
cells homozygous for HbS (SS RBCs) are characterized
by a panoply of abnormalities, including polymerization
of deoxygenated HbS [1,2], persistent oxidative mem-
brane damage associated with HbS cyclic polymerization
[3], abnormal activation of membrane cation transports,
cell dehydration [4], cytoskeletal dysfunction [5], and
increased adhesion [6]. These alterations in SS RBCs
lead to the complex pathophysiology associated with
SCD that includes vaso-occlusion, chronic hemolysis
and ischemic tissue damage [7].
Studies have suggested that oxidative [8,9] and physio-
logical stresses [10] are two of the prominent mechan-
isms leading to abnormalities in SS RBCs. These stresses
are thought to be propagated through alterations in nor-
mal protein phosphorylation events within complex
intracellular signaling pathways which may subsequently
affect protein structural stability [11,12], formation of
protein–protein complexes [13,14], activation of ion
transport leading to cell dehydration [15-17] and RBC
adhesive function [18,19]. Several proteins involved in
these pathways have been previously shown to be differ-
entially tyrosine phosphorylated in SS RBCs compared
to normal (AA) RBCs, including adducin, ankyrin 1, the
actin binding protein dematin, and protein band 4.1,
which stabilizes the spectrin-actin interaction [14,20].
Recently, we have shown that extracellular signal-
regulated kinase (ERK1/2) is hyperactive and can be indu-
cible in SS but not in AA RBCs, and can act downstream
of the cAMP/PKA/MEK1/2 pathway [18]. ERK1/2 is a
member of the large mitogen-activated protein kinase
(MAPK) family of serine/threonine kinases with a known
downstream target consensus motif of PX[pS/T]P [21-24].
ERK1/2 responds to stimulation by a variety of different
hormones, growth factors, and insulin [18,25-27] and med-
iates diverse functions including modulation of prolifera-
tion, differentiation, apoptosis, migration, and cell adhesion
[28-31]. Aberrations in ERK1/2 signaling have been previ-
ously reported to occur in a wide range of pathologies in-
cluding cancer, diabetes, viral infection, and cardiovascular
disease [32,33]. In SCD, abnormal ERK1/2 phosphorylation
and subsequent activation is involved in increased phos-
phorylation of SS RBC adhesion molecule ICAM-4, medi-
ating RBC adhesion to the endothelium, the phenotypic
hallmark of this disease [18]. It is still unknown, however,
which other erythrocyte membrane proteins might be
affected by the ERK1/2 signaling, and whether these pro-
teins contribute to the pathophysiology of SCD.
To further characterize global MEK1/2/ERK1/2-induced
changes in protein phosphorylation within human RBCs,we employed a previously established label-free quantita-
tive phosphoproteomics strategy to the plasma membrane
ghosts of human RBCs [18,34].
Results and discussion
Label-free quantitative phosphoproteomic profiling of
RBC membranes
LC-MS based quantitation of global (non-targeted)
phosphorylation events directly from human RBCs in
disease-affected patients has been very limited in the lit-
erature [12]. The most common analytical strategies
have employed coupling two-dimensional gel electro-
phoresis of solubilized RBC proteins with either global 32P
labeling or anti-phosphotyrosine detection antibodies, fol-
lowed by LC-MS/MS identification of phosphoproteins
from differentially expressed protein spots [12,35]. In
addition to the limited number of unique treatment con-
ditions, which could be directly compared within a single
study, these previous approaches do not allow residue-
specific quantitation of phosphorylation events as initial
detection in changes in phosphorylation status are mea-
sured at the protein level. This is particularly problematic
for proteins containing multiple sites of phosphorylation,
as each could be independently modulated by different
kinases or phosphatases as a function of various stimuli.
In addition, different phosphorylation sites could have dif-
ferent effect on protein function. Although strategies
such as iTRAQ, commonly used for phosphoproteo-
mic quantitation from non-cell culture based systems,
address some of these limitations, the reagents add
significant cost when performing the labeling at the
quantities of total protein required for phosphopro-
teomic analysis.
To further characterize global MEK1/2/ERK1/2-induced
changes in protein phosphorylation within human SS
RBCs, a global label-free quantitative phosphoproteo-
mic discovery analysis of SS and AA RBC plasma mem-
brane ghosts was performed [18]. To determine specific
involvement of the ERK1/2 activation in SS RBC mem-
brane protein phosphorylation, each population of SS
and AA RBCs was either treated or not treated with a
potent MEK1/2 inhibitor (MEKI), U0126, which specif-
ically inhibits ERK1/2 kinase activity. RBC membrane
ghosts prepared from the resulting four populations of
RBCs, were then either subsequently co-incubated in
the presence or absence of exogenous recombinant ac-
tive ERK2 (Figure 1A). Proteolytically digested mem-
brane fractions from each of these eight unique samples
were then subjected to a previously described label-free
quantitative phosphoproteomics workflow utilizing re-
producible TiO2 phosphopeptide enrichments followed
by selected ion chromatographic peak quantitation of
accurate-mass retention time aligned LC-MS/MS data
to allow direct quantitative comparisons to be made
Figure 1 Overview of the (A) experimental design and (B) analytical strategy of the label-free quantitative phosphoproteomic
workflow. RBC membrane ghosts from healthy (AA) or sickle (SS) patients were proteolytically digested and then subjected to a TiO2 based
phosphopeptide enrichment. Following LC-MS/MS analysis, all data files were subjected to AMRT alignment within Rosetta Elucidator and
selected ion chromatograms were generated from each phosphopeptide precursor ion to measure abundance.
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minimize total analysis time, each sample was analyzed
in analytical triplicate by a one-dimensional LC-MS/MS
analysis without any additional fractionation prior to
TiO2 enrichment.
Across all samples, 375 unique phosphopeptides (527
total phosphorylated residues) corresponding to 155
phosphoproteins were identified at a peptide spectral
false discovery rate of 1.0%. As localization of specific
phosphorylated residues is critical for defining kinase
specific events, all phosphopeptides were subjected to
ModLoc, a probability-based localization tool implemen-
ted within Rosetta Elucidator based on the AScorealgorithm [36] (Additional file 1 Figure S1A). Approxi-
mately 74% (348) of phosphorylated residues had Mod-
Loc scores above 15 (>90% probability of correct
localization), and 66% (310) had ModLoc scores above
20 (>99% probability of correct localization) (Additional
file 2 Table). To assess the quantitative robustness of the
label-free approach, the average technical coefficient of
variation (%CV) of retention-time aligned phosphory-
lated peptide intensities of triplicate measurements
within a treatment group were calculated (Additional file 2
Table). The mean %CV across all 375 phosphopeptides was
19.8%, with 80% of the signals having a %CVs less than
27.1% (Additional file 1 Figure S1B). The intensity of the
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tive site of ERK1/2 was used to assess inter-treatment
group variation, including variation from TiO2 phospho-
peptide enrichment, as activated ERK2 was spiked in equal
amounts to four of the eight samples. The average %CV of
this phosphopeptide within any treatment group was 7.0%,
and across all ERK2 spiked samples was 18.1% (Additional
file 3 Figures S2 A&B).
Consistent with a majority of TiO2-enrichment based
global mammalian phosphoproteomic studies, 79% (415)
of the identified phosphorylated residues were localized
to serines, 16% (85) to threonines, and 5% (27) to tyro-
sines, with an average of 1.4 phosphorylated residues per
peptide (Figure 2A). Gene ontology classification of the
biological function of the 155 identified phosphoproteins
indicated nearly a third of the phosphoproteins wereFigure 2 Phosphopeptide characteristics and phosphoprotein gene o
pThr, and pTyr containing phosphopeptides (top panel) and number of phos
membrane phosphopeptides. (B) NCBI Gene ontology of identified phosphopinvolved in binding as their primary biological function.
Sub-classification of the binding category revealed over
80% of those phosphoproteins were involved in either
protein binding (51%) or nucleotide binding (30%)
(Figure 2B). Phosphoproteins involved in ion binding
consisted 12% of the total phosphoproteins (Figure 2B).
As these RBC samples were prepared as membrane frac-
tions, the large number of membranous binding proteins
was not unexpected. Consistent with other RBC mem-
brane phosphorylation studies, the phosphoproteins of
SS RBC membrane ghosts with the highest number of
uniquely phosphorylated peptides (>10), were ankyrin-1
of the ankyrin complex, spectrin β chain of the cytoskel-
eton network, and proteins of the junctional complex,
including α- and β-adducins, dematin and protein 4.1
(Table 1). In addition, phosphoproteins with >5 uniquentology classification from RBC membranes. (A) Distribution of pSer,
phorylated residues per peptides (bottom panel) across all identified RBC
roteins implemented with Scaffold (Proteome Software).










Ankyrin-1 ANK1 33 23
Glyophorin A GYPA 23 8
Alpha-adducin ADD1 22 18
Beta-adducin ADD2 18 11
Protein 4.1 EPB41 17 13
Dematin EPB49 16 13

















Twelve unique phosphoproteins were identified by at least five unique
phosphopeptides. These included proteins of the ankyrin complex (ankyrin-1),
the cytoskeleton network (spectrin β chain) and the junctional complex
involved in binding integral membrane proteins to cytoskeletal proteins
(α- and β-adducins, dematin, and protein 4.1), which affect RBC shape,
flexibility and adhesion, or proteins that affect anion transport, protein
trafficking and adhesion (band 3 and glycophorin A), G protein activation
(GTPase activating protein), lipid biosynthesis (lipin 2) and serine/threonine
phosphorylation (serine/threonine protein kinase).
Figure 3 Two-dimensional (2D) agglomerative cluster analysis using Z
unique RBC treatment groups. Person correlations were used as the mea
branch point. (A) RBCs from healthy (AA) and sickle cell (SS) patients pre-tr
preparation of membrane ghosts, and their subsequent co-incubation with
only on SS (top panel) or AA (bottom panel) RBC treatment groups.
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flexibility, anion transport and protein trafficking, and
adhesion, all of which contribute to the pathophysiology
of SCD, were also observed (Table 1).ERK1/2 Induces atypical phosphorylation of SS RBC
membrane proteins
To assess global quantitative differences between all
treatment groups, data were subjected to two-dimensional
agglomerative clustering using Z-score transformed (i.e. mag-
nitude of significance of change) individual phosphopeptide
intensities (Figure 3A). This analysis revealed that the
most significant differentiation (most negative Pearson
correlation) across all treatment groups, was the sickle
versus healthy RBC phenotype, with 201 phosphopep-
tides being up-regulated in SS vs AA RBCs at a fold-
increase of >1.75. These thresholds were chosen based
on an alpha value corresponding to a 95% confidence
interval in a statistical powering calculation (http://
www.dssresearch.com/KnowledgeCenter/toolkitcalcula-
tors.aspx). The weight of variation from the SS to AA
RBC (−0.664) was more pronounced than the addition of
exogenous active ERK2 or the inhibition of MEK1/2 activ-
ity with the MEK1/2 inhibitor U0126 (Figure 3A), suggest-
ing that in addition to MEK1/2/ERK1/2 phosphorylation
cascades in the SS RBC, other cellular signaling pathway
activities may be involved. Interestingly, clustering of all
phosphopeptides within only the SS RBC samples revealed
the strongest differentiating factor was in the presence or-score transformed phosphopeptide intensities across eight
sure of similarity (−1 dissimilar, +1 identical) and are shown at each
eated with or without the MEK1/2 inhibitor, U0126, followed by
or without activated recombinant ERK2. (B) Cluster analysis performed
Soderblom et al. Clinical Proteomics 2013, 10:1 Page 6 of 16
http://www.clinicalproteomicsjournal.com/content/10/1/1absence of U0126 (Pearson correlation, -0.422) (Figures 3B,
top panel), which supports the previous observation that
ERK1/2 is constitutively hyperactive in these sickle RBCs
and that inhibiting ERK1/2’s upstream activator, MEK1/2,
alters a number of signaling events. Recovery from the
U1026 treatment by addition of exogenous active ERK2
resulted in the phosphorylation profile becoming more
similar to the non-treated SS RBCs (Figure 3B, top panel).
In comparison, clustering of all phosphopeptides within
only the AA RBC samples revealed the strongest differenti-
ating factor was the addition of exogenous active ERK2
(−0.489) (Figure 3B, bottom panel), which is consistent
with the normal inactivity of ERK1/2 in AA RBCs, and
suggests that ERK1/2 signaling is indeed mediating down-
stream phosphorylation of a number of targets.
Putative downstream targets specific to MEK1/2-
dependent activation of ERK1/2 were initially identified in
SS RBCs, in which 36 unique phosphopeptides (from 21
unique phosphoproteins) decreased in abundance upon
treatment with U0126. Basal ERK1/2 is already active in
SS RBCs and inactive in AA RBCs [18]. Therefore, in an
effort to keep the focus on the pathophysiological relevant
effect of the abnormal activation of MEK1/2/ERK1/2
signaling on RBC membrane protein phosphorylation,
we have presented the most physiologically relevant
treatment group comparisons: AA vs SS RBCs, SS vs SS
RBCs+U0126, SS vs SS RBCs+ERK2, SS+U0126 vs SS
RBCs+U0126+ERK2, and AA vs AA RBCs+ERK2 in
Table 2. Because label-free proteomics analysis revealed
that MEK1/2/ERK1/2 signal to down-regulate 36 phos-
phopeptides in SS RBCs, it was important to determine
the pathophysiological relevance of the abundance of
these phosphopeptides by first showing that their levels
were down-regulated in AA RBCs compared to SS
RBCs. Comparison of individual phosphopeptide inten-
sities between SS and AA RBCs indicates that out of
these 36 phosphorylated peptides in SS RBCs, the abun-
dance of only 25 of these phosphopeptides were
decreased in AA RBCs. A negative feedback mechanism
to down-regulate phosphorylation of the 25 phospho-
peptides may be inactive in SS RBCs. For instance, SS
RBCs have significantly higher levels of cAMP than AA
RBCs [18], and PKA has been shown to exert a negative
feedback loop through activation of phosphodiesterases,
resulting in cAMP hydrolysis switching off downstream
signaling [37]. While the MEK1/2 inhibitor U0126 was
able to down-regulate these 36 unique phosphopeptides
in SS RBCs, incubation of SS RBC membrane ghosts
with recombinant active ERK2 in contrast, failed to in-
crease abundance of these 36 phosphopeptides in SS
RBCs (Table 2). This suggests that these peptides are
already affected in SS RBCs by MEK/1/2/ERK1/2 signaling
cascade, and do not necessitate further modification by ex-
ogenous ERK2. Furthermore, recombinant ERK2 was notable to fully (100%) bring up to baseline the abundance of
all phosphopeptides down-regulated by U0126. As a re-
sult, 28 of these phosphopeptides did not reach the sig-
nificant fold-increase of >1.75 (Table 2).
We analyzed a number of these phosphoproteins refer-
ring first to the model of red blood cell membrane func-
tional organization proposed by Anong WA et al. who
identified two major protein complexes bridging the
RBC membrane to cytoskeleton network: the junctional
complex formed by band 3, glycophorin C, Rh group,
glucose transporter, dematin, p55, adducin, band 4.1 and
4.2 with associated glycolytic enzymes and the ankyrin
complex formed by band 3, glycophorin A, Rh group,
ankyrin, and protein 4.2. Both complexes participate in
anchoring the membrane to the actins, and α- and
β-spectrins network, involving also other peripheral pro-
teins as tropomyosin and tropomodulin [38]. Here, we
found that MEK1/2-dependent ERK1/2 activation in SS
RBCs affected membrane-bound proteomes of both the
junctional and ankyrin complexes, including dematin, α-
and β-adducins, and glycophorin A.
Glycophorin A was the most affected protein in SS
RBCs as a result of ERK1/2 activation, with 12 unique
phosphorylated peptides (8 unique phosphorylated resi-
dues) being decreased in response to U0126 treatment
(Table 2). The abundance of 7 of the phosphorylated resi-
dues, which were down-regulated with U0126 treatment
of SS RBCs, were up-regulated in AA RBCs when exogen-
ous active ERK2 was added to RBC membrane ghosts,
suggesting that increased phosphorylation of glycophorin
A by MEK1/2/ERK1/2 signaling could potentially affect SS
RBC membrane properties (Table 2). To assess the
changes of these phosphopeptides across the most rele-
vant treatment groups, Z-score transformed trend plot
analysis were performed and glycophorin A phosphopep-
tides were grouped by those which decreased in SS RBCs,
and correspondingly did (top panel, 5 unique peptides) or
did not (bottom panel, 7 unique peptides) increased in AA
RBCs with addition of active ERK2 to the membrane
ghosts (Figure 4A). For those phosphopeptides which
resulted in a corresponding increase in AA RBCs with
addition of recombinant ERK2, trend plot analysis were
performed across all eight treatment groups (Figure 4B).
Glycophorin A, is the major sialoglycoprotein and
increased SS RBC adhesion to vascular endothelial cells
has been postulated to result from clustering of nega-
tively charged glycophorin-linked sialic acid moieties at
the RBC surface [6,39]. Enhanced SS RBC adhesion may
also result from increased phosphorylation of glyco-
phorin A by MEK/1/2/ERK1/2 signaling. In addition,
modulation in glycophorin A phosphorylation may also
affect glycophorin A interactions with band 3, which
could result in decreased in both anion transport by
band 3 and band 3 trafficking.
Table 2 Differentially regulated phosphopeptides in SS RBCs in response to MEK1/2 inhibitor U0126


















KEES*EES*DDDMGFGLFD 4.8 (7.24E-20) −2.1 (3.61E-08) NS NS NS
Adenylyl cyclase-
associated protein 1
SGPKPFSAPKPQTS*PSPK NS −4.8 (2.00E-03) NS 5.3 (2.00E-04) NS
Alpha-adducin QKGS*EENLDEAR 2.5 (2.43E-33) −4.1 (2.80E-45) NS 2.4 (1.25E-11) NS
Beta-adducin ETAPEEPGS*PAKS*APAS*PVQSPAK 5.6 (3.72E-28) −1.9 (3.87E-09)* NS NS 2.4 (4.21E-06)*
Beta-adducin ETAPEEPGSPAKS*APAS*PVQSPAK NS −1.8 (1.80E-02)* NS 1.8 (3.00E-02) 1.8 (2.00E-02)*
Beta-adducin TESVTSGPMSPEGSPSKS*PSK NS −1.9 (3.00E-02) NS 1.9 (3.00E-03) NS
Dematin QPLTSPGSVS*PSR 7.9 (8.63E-05) −4.4 (1.00E-03) NS NS NS
E3 ubiquitin-protein
ligase UBR4
T*SPADHGGSVGSESGGSAVDSVAGEHSVSGR 3.6 (1.55E-18) −1.8 (1.02E-07) NS NS NS
Eukaryotic translation
initiation factor 4B
SQS*SDTEQQSPTSGGGK 5.6 (9.74E-06) −2.5 (4.00E-03) NS 2.0 (2.00E-02) NS
facilitated glucose
transporter member 1
QGGAS*QSDKTPEELFHPLGADSQV 5.0 (7.45E-10) −3.4 (7.99E-08) NS NS NS
Glycophorin-A KS*PSDVKPLPSPDTDVPLSSVEIENPETS*DQ 7.7 (9.74E-07) −1.9 (2.10E-02) NS NS 2.0 (5.00E-03)
Glycophorin-A KSPSDVKPLPS*PDT*DVPLS*SVEIENPETSDQ 10.2 (1.05E-06) −2.3 (5.00E-03) NS NS 2.1 (8.04E-04)
Glycophorin-A S*PS*DVKPLPSPDTDVPLSSVEIENPETS*DQ 6.3 (9.08E-07) −2.0 (1.60E-02) NS NS 1.9 (3.10E-02)
Glycophorin-A S*PS*DVKPLPSPDTDVPLSSVEIENPETSDQ 6.3 (9.08E-07) −2.0 (8.00E-03) NS NS NS
Glycophorin-A SPSDVKPLPS*PDT*DVPLS*SVEIENPETSDQ 7.4 (8.28E-06) −1.9 (2.90E-02) NS NS 1.9 (6.00E-03)
Glycophorin-A SPSDVKPLPS*PDT*DVPLSSVEIENPETSDQ 5.0 (0.00E+00) −2.0 (2.13E-07) NS NS NS
Glycophorin-A SPSDVKPLPSPDT*DVPLS*SVEIENPETSDQ 5.0 (0.00E+00) −1.8 (4.80E-02) NS NS NS
Glycophorin-A SPSDVKPLPSPDT*DVPLSSVEIENPETSDQ 5.0 (0.00E+00) −2.0 (2.59E-21) NS NS NS
Glycophorin-A SPSDVKPLPSPDTDVPLS*S*VEIENPETSDQ 5.1 (3.49E-06) −2.2 (3.00E-03) NS NS 2.7 (7.97E-05)
Glycophorin-A SPSDVKPLPSPDTDVPLSS*VEIENPETSDQ NS −1.9 (3.30E-07) NS NS NS
Glycophorin-A SPSDVKPLPSPDTDVPLSSVEIENPET*SDQ NS −1.9 (1.82E-13) NS NS NS








MAGPGST*GGQIGAAALAGGAR 88.6 (1.70E-02) −6.5 (4.50E-02) NS 6.7 (4.54E-06) NS


















Table 2 Differentially regulated phosphopeptides in SS RBCs in response to MEK1/2 inhibitor U0126 (Continued)
Metabotropic
glutamate receptor 7
LSHKPSDRPNGEAKT*ELCENVDPNS*PAAK 2.4 (1.61E-15) −1.9 (2.95E-09) NS NS 2.3 (7.98E-15)
Proteasome subunit
alpha type-3
ESLKEEDES*DDDNM 2.8 (4.14E-11) −1.8 (5.42E-06) NS NS NS
Protein MICAL-2 VS*S*GIGAAAEVLVNLY*MNDHRPKAQAT*SPDLESMRK NS −4.1 (8.44E-05) NS NS NS
Protein Wnt-16 HERWNCMITAAATTAPMGASPLFGYELS*SGTK −2.2 (5.13E-05) −2.0 (1.90E-02) NS NS NS
Spectrin beta chain,
erythrocyte
LS*SS*WESLQPEPSHPY 3.5 (4.17E-13) −1.8 (5.56E-05) NS NS 2.0 (9.30E-11)
Spectrin beta chain,
erythrocyte
QIAERPAEETGPQEEEGETAGEAPVS*HHAATER 2.1 (6.00E-03) −2.4 (5.77E-04) NS NS NS
Transmembrane protein
151B




VVHS*FDYAAS*ILSLALAHEDETIVVGMTNGILS*VKHR NS −2.9 (7.39E-11) NS 2.2 (6.08E-05) 2.1 (9.39E-14)
Uncharacterized
protein LOC388588
DGVS*LGAVS*STEEASR NS −1.8 (9.99E-05) NS NS 2.2 (2.40E-09)
Uncharacterized protein
LOC388588




EDKS*PSEESAPTTSPESVSGSVPSSGSSGR 5.0 (6.40E-38) −2.0 (1.96E-14) NS NS 2.2 (4.13E-32)
36 unique phosphorylated peptides were statistically down-regulated in SS RBCs upon treatment with the MEK1/2 inhibitor U0126 (SS vs SS+U0126). Of these 36, 8 phosphopeptides had their levels increased back to
near basal levels upon exogenous addition of active ERK2 (SS+U0126 vs SS+U0126+ERK2). Thirteen of these phosphorylated peptides were also observed to be increased in AA RBCs upon exogenous addition of active
ERK2 (AA vs AA+ERK2), suggesting specificity of downstream ERK activity. p-values < 0.05 indicate the statistically significant variances associated with differences within triplicates for that particular comparison.
Biological variances associated with differences within groups are not included in these p-values. (*) indicates previously reported values [18]. NS, which refers to non-significant, indicates that a statistically significant
















Glycophorin-A phosphopeptides down-regulated in SS in response to 
U0126 and concurrently up-regulated in AA in response to ERK
Glycophorin-A phosphopeptides down-regulated in SS in response to 















Figure 4 (See legend on next page.)
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Figure 4 Trend plot analysis of differentially expressed glycophorin-A phosphopeptides. (A) Z-Score transformed phosphopeptide
intensities of glycophorin-A peptides, which decreased in abundance in SS RBCs upon treatment with U0126 (indicated in Table 2) were
differentiated into groups, which either did or did not increased in AA RBCs upon addition of recombinant active ERK2 to the membrane ghosts,
and plotted across four relevant treatment groups. (B) Five glycophorin-A phosphorylated peptides, which both decreased in SS RBCs upon
treatment with U0126 and increased in AA RBCs upon addition of active ERK2 to the membrane ghosts plotted across all eight treatment groups.
Each data-point is plotted as an average of three technical replicates. An (*) within the peptide sequence indicates the preceding residue is
phosphorylated.
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unique phosphorylated peptides, with phosphorylation of
residues within the ERK1/2 consensus motif [18], sug-
gesting that the cytoskeletal protein adducin-β is a sub-
strate for ERK1/2 in RBCs (Table 2). A decrease in
phosphorylation of these peptides was observed in
U0126-treated SS RBCs, while an increase in phosphor-
ylation was observed in both U0126-treated SS RBCs
and in AA RBCs when recombinant active ERK2 was
added to the membrane ghosts. However, the phosphory-
lated serine on either adducin-α or dematin, was not
within the ERK1/2 consensus motif [18]. Phosphoryl-
ation of cytoskeletal proteins by ERK1/2 in SS RBCs may
lead to cytoskeletal disorganization [14,40-43], which in
turn, could potentially affect RBC adhesiveness. Our pre-
vious study has indeed shown that ERK1/2 regulates SS
RBC adhesion to the endothelium [18]. Furthermore,
while protein 4.1 in SS RBCs is extensively phosphory-
lated [14] with 17 uniquely phosphorylated peptides and
13 unique phosphorylated residues (Table 1), based on
the chosen threshold fold-increase of >1.75 for this
study, increased phosphorylation of protein 4.1 seems to
not involve ERK1/2 signaling.
MEK1/2/ERK1/2 signaling in SS RBCs induced changes
within the actins/spectrins network as well by affecting
phosphorylation of β-spectrins (Table 2). Erythrocyte spec-
trin, the major component of the membrane skeleton,
undergoes a number of naturally occurring or pathologic-
ally induced posttranslational phosphorylation via a cAMP-
dependent protein kinase [44,45], which has been shown to
act upstream of ERK1/2 in SS RBCs [18]. 32P-labeling
studies indicate that only the β-subunit of spectrin is
phosphorylated in intact erythrocyte [44,46-48], and an
increase in β-spectrin phosphorylation by casein kinase
I causes a decrease in erythrocyte membrane mechan-
ical stability [49].
Furthermore, this analysis revealed that the peptide
metabotropic glutamate receptor 7 (mGlu7) underwent
serine phosphorylation at the ERK consensus motif
(Table 2). In addition, a phosphopeptide detected within
mGlu7 in our dataset was increased in SS RBCs by 2.4-
fold compared to healthy AA RBCs. Gu et al. have also
shown that mGluR7 activation occurs via an ERK-
dependent mechanism, which increased cofilin activity
and F-actin depolymerization [50]. mGLu7 acts as anautoreceptor mediating the feedback inhibition of glu-
tamate release [51-53], and prolonged activation of this
receptor potentiates glutamate release [54]. Changes
were also observed in the status of leucine-rich repeats
and immunoglobulin-like domains protein 2, leucine-
zipper-like transcriptional regulator 1, and glucose trans-
porter 1, but only in membrane ghosts prepared from SS
RBCs treated with U0126 or after addition of exogenous
active ERK2 to these membrane ghosts (Table 2).
Changes in the status of these proteins by MEK1/2/
ERK1/2 signaling may potentially disturb degradation of
misfolded glycoproteins and receptor ubiquitination, and
affect protein transcription. Similarly, phosphorylation of
adenylyl cyclase-associated protein 1 (CAP1), which was
more abundant in SS vs AA RBCs, increased via the
ERK1/2 signaling only in SS RBCs [18]. CAP1 is known
to regulate adenylate cyclase activation to increase
cAMP levels under specific environmental conditions.
Indeed, basal cAMP levels are much higher in sickle
than in healthy RBCs, and cAMP/PKA can regulate
ERK1/2 activation in SS RBCs [18]. CAPs are also
involved in actin binding, SH3 binding, and cell morph-
ology maintenance as well [55,56]. The failure of recom-
binant active ERK2 to significantly up-regulate the
abundance of the phosphorylated peptides, leucine-rich
repeats and immunoglobulin-like domains protein 2,
leucine-zipper-like transcriptional regulator 1 and CAP1
in healthy RBCs suggests a negative regulatory mechanism
might exist in these cells to prevent activation of ERK1/2-
dependent phosphorylation of these membrane proteins,
such as the ability of PKA to negatively affect phospho-
diesterases to switch off downstream signaling [37].
ERK1/2 Signaling highly affects phosphorylation of
glycophorin A
The pharmacological stress hormone epinephrine can in-
crease ERK1/2 activation in SS RBCs [18]. Because our
discovery proteomics data indicated that the MEK1/2 in-
hibitor U0126 down-regulated the phosphorylation state
of glycophorin A in a number of unique residues, we
determined the contribution of activation of MEK1/2-
dependent ERK1/2 signaling in glycophorin A phosphoryl-
ation in intact SS RBCs. SS RBCs were therefore treated
with epinephrine to increase activation of ERK1/2 in the
presence or absence of the MEK inhibitor U0126 prior to
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analysis of immunoprecipitated 32P-radiolabeled glyco-
phorin A and negative control immune complexes showed
that glycophorin A of non-stimulated SS RBCs (Figure 5,
lane 1, patient 1) is modestly phosphorylated at baseline,
which confirms our phosphoproteomics data (Table 2).
Treatment of SS RBCs with serine phosphatase inhibitors
(SPI) (lane 2, patients 1; and lane 1, patient 2) slightly
increased glycophorin A phosphorylation by 1.9±0.1-fold
(p<0.05, n=3), suggesting that increased glycophorin A
phosphorylation is a result of serine phosphorylation, as
tyrosine phosphatase inhibitors were not present. Epi-
nephrine in the presence of SPI had a stronger effect on
glycophorin A phosphorylation (2.93±0.35-fold increase
over sham-treated SS RBCs; p<0.001) (lane 3, patient 1;
and lane 2, patient 2). However, treatment of SS RBCs
with the MEK/12 inhibitor U0126 significantly decreased
the combined effect of epinephrine and SPI on glyco-
phorin A phosphorylation (lane 4, patient 1; and lane 3,
patient 2) compared to cells treated with epinephrine and
SPI (p<0.001) (lane 3 patient 1; and lane 2, patient 2).
Immunoblots of 32P-radiolabeled glycophorin A immuno-
precipitates from stimulated and non-stimulated SS RBCs
indicated that a similar amount of glycophorin A was
immunoprecipitated from these cells (Figure 5). Our data
strongly confirm that increased glycophorin A phosphor-
ylation is dependent on MEK1/2-dependent ERK1/2 sig-


























Figure 5 ERK1/2 signaling up-regulates glycophorin A serine pho
incubated in the absence (patient 1: lane 1) or presence (patients 1: lanes 2
phosphatase inhibitors (SPI), not followed (patient 1: lanes 1 and 2; and pa
1: lanes 3 and 4; and patient 2: lanes 2 and 3). In lane 4 (patient 1) and lan
U0126 prior to treatment with SPI followed by epi treatment. The Fold cha
calculated after subtraction of cpm present in a lane (not shown) containin
using anti-glycophorin A mAb for immunoprecipitation under each set of c
treated vs. sham-treated, respectively; **: p<0.001 compared to SPI+epi-trea
using nitrocellulose membranes of phosphorylated glycophorin A blotted wglycophorin contains receptors or other surface recogni-
tion sites of the erythrocyte [57]. Although the conform-
ation of glycophorin in the lipid bilayer is not known, it
has also been suggested that the glycoproteins exist as
aggregates in the membrane in order to facilitate receptor
function [58]. However, we do not know whether
increased phosphorylation of glycophorin A affects the
state of aggregation of this glycoprotein. Recently, Shapiro
and Marchesi have demonstrated that the site of phos-
phorylation of glycophorin is located on the C-terminal
portion of the protein [59]. Indeed, localization of all iden-
tified phosphorylated resides in these data were located on
the C-terminal 30 residues of the protein. It remains to be
determined if phosphorylation plays a role in the forma-
tion of aggregates of the protein.
Conclusion
To date, a quantitative LC-MS based analysis of global
phosphorylation events in a membrane fraction of sickle
RBCs has not been reported in the literature. Here we
applied a label-free quantitative phosphoproteomic strat-
egy to characterize signaling pathways from healthy and
sickle RBC membrane fractions in the presence or ab-
sence of a specific MEK1/2 inhibitor with and without
subsequent ERK2 activation. The analysis resulted in the
quantitation of 375 phosphopeptides from 155 unique
phosphoproteins with an average technical coefficient of
variation in peak intensity of 19.8%. Gene ontology*
**
sphorylation. Inorganic 32P radiolabeled intact SS RBCs were
, 3 and 4; and patient 2: lanes 1, 2 and 3) of serine/threonine protein
tient 2: lane 1) or followed by treatment with epinephrine (epi) (patient
e 3 (patient 2), SS RBCs were preincubated with MEK1/2 inhibitor
nge in phosphorylation is representative of three different experiments,
g immunoprecipitates using immunoglobulin P3 from cpm obtained
onditions indicated. *: p<0.05 and p<0.001 for SPI-treated and SPI+epi-
ted SS RBCs. Total glycophorin A loaded in each lane was detected
ith anti-glycophorin A mAb.
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phoproteins are involved in binding as their primary bio-
logical function. This is of considerable importance as the
primary hallmark of sickle cell disease is the ability of
RBCs to abnormally interact with endothelial cells, leuko-
cytes and platelets, and these cell-cell interactions are
mediated through activation of RBC surface adhesion
receptors. It is important to note that the goal of this work
was to perform a discovery experiment to identify candi-
date proteins differentially regulated by the ERK1/2 signal-
ing pathway (Table 2). As we knew biological replications
would not be available, we addressed the replication of the
most biologically relevant and novel findings (phosphoryl-
ation of glycophorin A) through additional biochemical
assays on replicate patients (Figure 5).
Phosphopeptide quantitation across all eight unique
treatment groups indicate that the ERK1/2 pathway activa-
tion in SS RBCs could be responsible for alteration of mul-
tiple phenotypic and functional properties of the red cell,
by affecting phosphorylation of thirty-six peptides from
twenty-one phosphoproteins involved in adhesion, cAMP
production, anion transport by band 3 and band 3 traffick-
ing, RBC shape, flexibility, cell morphology maintenance,
glucose and glutamate transport, degradation of misfolded
proteins, and receptor ubiquitination, all of which play a
significant role in the complex pathophysiology of the dis-
ease. Interestingly, these data revealed that glycophorin A
phosphorylation was highly differentiated between healthy
and sickle RBCs, and its levels of phosphorylation were
modulated by the presence of the MEK1/2 inhibitor U0126
and the presence of exogenously spiked ERK2. Glyco-
phorin A is the major sialoglycoprotein, and increased SS
RBC adhesion to vascular endothelial cells has been postu-
lated to result from clustering of negatively charged
glycophorin-linked sialic acid moieties at the RBC surface
[6,39]. In addition, alteration in glycophorin A phosphoryl-
ation could subsequently result in decreases in both anion
transport by band 3 and band 3 trafficking. Thus, our stud-
ies further confirm ERK1/2 as a potential therapeutic target
to ameliorate multiple functions of the sickle red cell, in-
cluding adhesion [18] and vaso-occlusion [10,18], chronic
hemolysis and ischemic tissue damage [7], all of which are
associated with the pathophysiology of SCD. Finally,
follow-up validations will be addressed on additional
physiologically relevant molecules presented in Table 2,
such as cytoskeletal proteins, and the effect of their phos-
phorylation by ERK1/2 on RBC function.
Materials and methods
Collection, preparation and treatment of RBCs
Human SCD patients homozygous for hemoglobin S were
not transfused for at least three months, had not experi-
enced vaso-occlusion for three weeks and were not on
hydroxyurea. Blood samples from SCD patients andhealthy donors collected into citrate tubes, were used
within less than 24 h of collection. Packed RBCs were
separated as previously described in detail [60]. Packed
RBCs were analyzed for leukocyte and platelet contamin-
ation using an Automated Hematology Analyzer K-1000
(Sysmex, Japan). For proteomics studies, aliquots of
packed RBCs were treated at 37°C for 1 h with 10 μM
MEK1/2 inhibitor U0126 dissolved in dimethyl sulfoxide
(DMSO). Sham-treated RBCs were incubated with the
same buffer and vehicle, but without the active agent. Nor-
mal RBCs were used as controls.
MAP kinase activity assay
Treated packed normal and SS RBCs were lysed at 4°C
with lysis buffer (10 mM EDTA, 20 mM Tris, 110 mM
NaCl, pH 7.5) containing 2 mM PMSF, 1% Triton
X-100, phosphatase inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO) and protease inhibitor cocktail (Sigma). RBC
membrane ghosts were then incubated with or without
recombinant active human ERK2 (Sigma) at 8.2 μg/ml
with a specific activity of 700 nmole/min/mg, in the
presence of inhibitors of PKA, PKC, Ca2+/calmodulin-
dependent kinase and p34cdc2 kinase to prevent nonspe-
cific protein phosphorylation by these enzymes [61], and
with ATP as a phosphate donor with equal membrane
ghost protein amounts per assay condition. For the
negative control, an equal volume of water was substi-
tuted for ATP. The reaction mixture was incubated for
20 min at 30°C. To stop the enzymatic reaction samples
were placed on ice.
RBC membrane ghost preparation and phosphopeptide
enrichment
Non-radiolabeled RBC membrane ghosts isolated from
packed RBCs sham-treated or treated with U0126 and
incubated with or without recombinant ERK2, were
spun at 14,000 rpm for 15 min at 4°C to pellet mem-
branes. Membrane pellets were washed with 1 mL 50 mM
ammonium bicarbonate (pH 8.0) with vortexing and
were then spun at 14,000 rpm for 30 min at 4°C. The
supernatant was then removed and 500 μL of 0.2%
acid-labile surfactant ALS-1 (synthesized in house
according to Yu et al. [62]) in 50 mM ammonium bicar-
bonate (pH 8.0) was added. Samples were subjected to
probe sonication three-times for 5 sec with cooling on
ice between and insoluble material was cleared by cen-
trifugation at 14,000 rpm for 30 min at 4°C. Samples
were normalized to approximately 2 μg/μl following a
micro-Bradford assay (Pierce Biotechnology, Inc), and
were reduced with a final concentration of 10 mM
dithiothreitol at 80°C for 20 min. Samples were then
alkylated with a final concentration of 20 mM iodoaceta-
mide at room temperature for 45 min and trypsin was
added to a final ratio of 1-to-50 (w/w) enzyme-to-protein
Soderblom et al. Clinical Proteomics 2013, 10:1 Page 13 of 16
http://www.clinicalproteomicsjournal.com/content/10/1/1and allowed to digest at 37°C for 18 hr. To remove ALS-1,
samples were acidified to pH 2.0 with neat TFA, incubated
at 60°C for 2 hrs and spun at 14,000 rpm for 5 min to re-
move hydrolyzed ALS-1. Samples were either subjected to
LC-MS analysis following a 10X dilution into mobile
phase A or subjected to a TiO2 based phosphopeptide
enriched protocol [34].
To enrich for phosphorylated peptides prior to LC-MS
analysis, 1,125 μg of total digested protein from RBC
ghosts were brought to near dryness using vacuum cen-
trifugation and then resuspended in 200 μL of 80%
acetonitrile, 1% TFA, 50 mg/ml MassPrep Enhancer
(pH 2.5) (Waters Corp., Milford, MA). Samples were
loaded onto an in-house packed TiO2 spin column (Protea
Biosciences) with a 562 μg binding capacity pre-
equilibrated with 80% acetonitrile, 1% TFA (pH 2.5). For
all loading, washing, and elution steps, the centrifuge was
set to achieve a flow rate of no faster than 100 μL/min.
Samples were washed twice with 200 μL 80% aceto-
nitrile, 1% TFA, 50 mg/ml MassPrep Enhancer (pH 2.5)
followed by two washes with 200 μL 80% acetonitrile,
1% TFA (pH 2.5). Retained peptides were eluted twice
with 100 μL 20% acetonitrile, 5% aqueous ammonia
(pH 10.0), acidified to pH 3 with neat formic acid and
then brought to dryness using vacuum centrifugation.
Prior to LC-MS analysis, each sample was resuspended
in 20 μL 2% acetonitrile, 0.1% TFA, 25 mM citric acid
(pH 2.5).
LC-MS/MS analysis of RBC membrane ghosts
Chromatographic separation of phosphopeptide enriched
or non-enriched samples was performed on a Waters
NanoAquity UPLC equipped with a 1.7 μm BEH130 C18
75 μm I.D. X 250 mm reversed-phase column. The mo-
bile phase consisted of (A) 0.1% formic acid in water
and (B) 0.1% formic acid in acetonitrile. Five μL injec-
tions of each sample were trapped for 5 min on a 5 μm
Symmetry C18 180 μm I.D. X 20 mm column at 20 μl/
min in 99.9% A. The analytical column was then
switched in-line and the mobile phase was held for 5
min at 5% B before applying a linear elution gradient of
5% B to 40% B over 90 min at 300 nL/min. The analyt-
ical column was connected to fused silica PicoTip emit-
ter (New Objective, Cambridge, MA) with a 10 μm tip
orifice and coupled to the mass spectrometer through
an electrospray interface.
MS was acquired on a Thermo LTQ-Orbitrap XL
mass spectrometer operating in positive-ion mode with
an electrospray voltage of 2.0 kV with real-time lock-
mass correction on ambient polycyclodimethylsiloxane
(m/z 445.120025) enabled. The instrument was set to
acquire a precursor MS scan from m/z 400–2000 with
r = 60,000 at m/z 400 and a target AGC setting of 1e6 ions.
MS/MS spectra were acquired in the linear ion-trap for thetop 5 most abundant precursor ions above a threshold of
500 counts. Maximum fill times were set to 1000 ms for
full MS scans acquired in the OT and 250 ms for MS/MS
acquired in the linear ion trap, with a CID energy setting
of 35% and a dynamic exclusion of 60 s for previously frag-
mented precursor ions. Multistage activation (MSA) for
neutral losses of 98.0, 49.0, and 32.33 Da was enabled to
enhance fragmentation of phosphorylated peptides.
Label-free quantitation and database searching
Label-free quantitation and integration of qualitative
peptide identifications was performed using Rosetta Elu-
cidator (v 3.3, Rosetta Inpharmatics, Seattle, WA). All
raw LC-MS/MS data were imported and subjected to
chromatographic retention time alignment using the
PeakTellerW algorithm with a minimum peak time width
set to 6 s, alignment search distance set to 4 min and
the refine alignment option enabled. Quantitation of all
detected signals in the precursor MS spectra was per-
formed within Elucidator following the generation of
extracted ion chromatograms for each detected precur-
sor ion. Fold-change values between treatment groups
were calculated on the phosphopeptide level from the
averages of the sum of all features associated with the
precursor ion within a technical replicate. To account
for slight differences in total peptide loading between
injections, all of the features within an LC-MS analysis
were subjected to a robust mean normalization of all of
the feature intensities, which excluded the highest and
lowest 10% of the signals.
Qualitative peptide identifications were made by gen-
erating DTA files for all precursor ions, which had asso-
ciated MS/MS spectra. DTA files were submitted to
Mascot (version 2.2.04, Matrix Science, Boston, MA)
and searched against a Homo sapiens protein database
downloaded from SwissProt concatenated with the
sequence-reversed version of each entry (download
March 2009, 20336 forward entries). Search tolerances
of 10 ppm precursor and 0.8 Da product ions were ap-
plied and all data were searched using trypsin specificity
with up to two missed cleavages. Static modification of
Carbamidomethylation (+57.0214 Da on C) and dynamic
modifications of oxidation (+15.9949 Da on M) and
phosphorylation (+79.9663 Da on STY) were employed.
False-discovery rate were determined by adjusting the
Mascot peptide ion score threshold to allow a 1% occur-
rence of peptide spectral matches from reverse protein
entries for phosphopeptide enriched experiments.
A tabular form of the raw data, including Protein Ac-
cession number, Protein Description, Modified Peptide
Sequence, ModLoc Max Score, Mascot Ion Score, and
Intensities/Standard Deviation for each phosphorylated
peptide within each treatment group has been uploaded
as an Additional file 2.
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Packed RBCs 32P-labeled as previously described [63], were
sham-treated, or incubated with serine/threonine phos-
phatase inhibitor (SPI) cocktail (Sigma) for 30 min, SPI
cocktail followed by 1 min treatment with 20 nM epineph-
rine, or pre-incubated with 10 μM U0126 for 1 h followed
by SPI cocktail, then treated with 20 nM epinephrine for 1
min. Cells were then washed 4 times. Glycophorin A
immunoprecipitation using anti-glycophorin A monoclonal
antibody (mAb) (Abcam, Cambridge, MA) and the nega-
tive control immunoglobulin P3, and total and phospho-
glycophorin A detection were performed as previously
described in detail [60]. To confirm that the immunopreci-
pitates were specific for glycophorin A, anti-glycophorin A
mAb and the negative control P3 were used to immuno-
precipitate glycophorin A from non-radiolabeled treated
SS RBCs. Blots were immunostained with anti-glycophorin
A mAb.
Data clustering and statistical analysis
Global characterization of phosphoproteomic profiles
across all treatment groups was accomplished using two-
dimensional clustering within Rosetta Elucidator. Individ-
ual phosphopeptide intensities within a treatment group
were averaged and then converted to a Z-score to measure
significance of change rather than absolute change. Z-score
corrected phosphopeptide intensities were then subjected
to an agglomerative clustering algorithm, using an average
link heuristic criteria. Pearson correlation metrics were
used to define similarity, with a score of 1 being identical
and −1 being completely dissimilar. P-values for phospho-
proteomic data was calculated using a ratio error model
[64]. P32 glycophorin-A data were compared using para-
metric analyses (GraphPad Prism 5 Software, San Diego,
CA), including repeated and non-repeated measures of
analysis of variance (ANOVA). One-way and two-way
ANOVA analyses were followed by Bonferroni corrections
for multiple comparisons (multiplying the p value by the
number of comparisons). A p-value < 0.05 was considered
significant.
Additional files
Additional file 1: Figure S1. Phosphorylated residue localization and
technical variation of phosphorylated peak intensity. (A) ModLoc site
localization scoring distributions across all 375 unique phosphoryalted
peptides from RBC ghost preparations. (B) Coefficient of variation (%CV)
distribution of measured phosphopeptide peak intensities from triplicate
LC-MS analysis of a treatment group following accurate-mass and
retention time alignment. Error bars indicate standard deviation within
each %CV bin across all eight treatment groups.
Additional file 2: Phosphopeptides identified in TiO2-enriched RBC
membrane fractions. From left to right; protein accession number,
protein description, modified peptide sequence, ModLoc Max Score,
Mascot ion score, and Intensities/Standard Deviation for each
phosphorylated peptide within each treatment group.Additional file 3: Figure S2. Inter-treatment group variation of ERK
phosphorylated peptide. Selected ion chromatogram (A) and peak
quantitation (B) of 173-VADPDHDHTGFLTE[pY]VATR-191 ([M+3H]3+
741.999 m/z), the active form of Mitogen-Activated Protein Kinase-1
(SwissProt_MAPK1, ERK1/2), across 24 LC-MS injections. This peptide
was qualitatively identified with a maximum mascot ion score of 63.3
and a site localization ModLoc score of 41 +/− 12.
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